Immune-Boosting drug tested for blood disorder in patients out of options
NCT ID NCT04823624
Summary
This study tested an experimental drug called MBG453 for adults with a lower-risk form of myelodysplastic syndromes (MDS), a bone marrow disorder. The drug is designed to help the patient's own immune system better recognize and attack the abnormal blood cells. The trial was for patients whose disease had progressed or who could not tolerate standard frontline treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.